Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice?

Arch Dermatol. 2011 Jul;147(7):855-6. doi: 10.1001/archdermatol.2011.167.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Bacterial Infections / chemically induced
  • Bacterial Infections / immunology
  • Contraindications
  • Humans
  • Pemphigoid, Benign Mucous Membrane / drug therapy*
  • Pemphigoid, Benign Mucous Membrane / immunology
  • Rituximab
  • Severity of Illness Index
  • Virus Diseases / immunology

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab